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Background: Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) with fibrous stromal
invasion are newly introduced subtypes of small lung adenocarcinoma. AIS is a small localized adenocarcinoma in
which growth is restricted to neoplastic cells along preexisting alveolar structures without fibrous stromal invasion.
In MIA, by contrast, tumor cells have infiltrated the myofibroblastic stroma. Transforming growth factor (TGF)-β is
known to be produced by progressor tumors, and excessive TGF-β contributes to a pathological excess of tissue
fibrosis. TGF-β1 is the most abundant isoform, and its expression is a key event fostering tumor invasion and
metastasis. We therefore analyzed the relationship between TGF-β1 expression and clinicopathological
microinvasion in patients with small lung adenocarcinoma.
Methods: The study participants were 45 patients who underwent curative surgery for AIS and MIA 3 cm or less in
size. Those tumors were assessed based on immunohistochemical staining using anti-TGF-β1 antibody. The TGF-β1
status was assessed immunohistochemically using the Allred 8-unit system.
Results: The rates of TGF-β1 positivity in the AIS and MIA groups were 27.3% and 65.2%, respectively (P <0.05). The
median of Allred score was 0.5 (range 0–5) in the AIS group and 3.0 (range 0–6) in the MIA group (P = 0.0017).
Conclusions: We suggest that TGF-β1 expression is likely to be significantly stronger in patients with MIA than in
those with AIS, and the increased expression may be associated with minimal invasion and infiltration of the
myofibroblastic stroma.
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factor-β1Background
Adenocarcinoma is the most common histological type
among lung cancers. As with malignancies in other
organs such as the breast and cervix, where carcinomas
are defined as non-invasive, micro-invasive or invasive,
the extent of the invasive component in lung adenocarcin-
omas is associated with clinical outcomes [1]. To address
advances in oncology, molecular biology, pathology, radi-
ology, and surgery, an international multidisciplinary* Correspondence: i-karo@mui.biglobe.ne.jp
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[2]. Adenocarcinoma in situ (AIS) and minimally invasive
adenocarcinoma (MIA) with fibrous stromal invasion are
newly introduced subtypes, while the older term of
bronchioloalveolar carcinoma does no longer exist
according to new IASLC classification of lung adenocar-
cinoma. AIS is a localized small (≤3 cm) adenocarcinoma,
the growth of which is restricted to neoplastic cells along
preexisting alveolar structures without stromal, vascular
or pleural invasion. Papillary or micropapillary patterns
and intra-alveolar tumor cells are absent. MIA is a small,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical details of all patients who underwent
pulmonary resection for small lung adenocarcinoma
AIS MIA P value
n 22 23
Age (year) 63±11.9 67±9.3 0.232
Gender (M/F) 8/14 8/15 0.675









AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, *P <0.05.
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lepidic pattern and showing ≤5 mm invasion in its greatest
dimension at any one focus. If these tumors are com-
pletely resected, there will be 100% or near 100% disease-
specific survival.
Transforming growth factor (TGF)-β reportedly pro-
motes cancer metastasis by affecting the tumor micro-
environment in a manner that facilitates tumor cell
invasion [3,4]. Several tumors, including those arising in
the lung [5-7], express high levels of TGF-β, which cor-
relate with tumor progression and clinical prognosis.
Humans express three highly homologous isoforms of
TGF-β (TGF-βs 1, 2, and 3), which share 70% sequence
identity in their biologically active C-terminal regions,
and all of which bind to the same receptor complex and
activate the same downstream signaling pathways. TGF-
β1 is the most abundant and most extensively studied
isoform [8].
We previously showed that tumor-derived TGF-β1
causes a reduction in the number of dendritic cells within
the sentinel lymph node in lung cancer [9]. Our findings
also suggest that TGF-β1 29T>C genetic polymorphism is
associated with lymph node metastasis in patients with
adenocarcinoma of the lung [10]. In addition, we showed
that overexpression of TGF-β1 by tumor cells promotes
metastasis into tumor-draining lymph nodes in mice, most
likely by inhibiting dendritic cell migration from tumors
towards tumor-draining nodes [11]. Collectively, these
results suggest that TGF-β1 is a key mediator fostering
tumor invasion and metastasis. We therefore analyzed the
relationship between TGF-β1 expression and clinico-




In total, 453 patients who had undergone major pulmon-
ary resections for non-small cell lung cancer (NSCLC)
were enrolled in the study. Among them, 45 patients
(10.1%) with NSCLC had AIS and MIA subtypes of small
lung adenocarcinoma 3 cm or less in size. All had under-
gone surgery in the Department of Chest, Breast and
Endocrine Surgery, University Hospital of Akita University
Graduate School of Medicine, between January 2004 and
December 2011. This study was approved by our institu-
tional review boards, and written informed consent was
obtained from all patients. The patients’ characteristics are
listed in Table 1. The 7th edition of the TNM staging sys-
tem was used for evaluation [12].
Pathology
Surgically resected specimens were fixed in 10% formalin
and routinely processed for paraffin embedding. Histo-
logical sections were cut into 4-mm slices, which werethen stained with hematoxylin and eosin (HE) and elastica
Masson using standard methods, and were reviewed by
two pathologists (A.G. and H.N.). Experienced patholo-
gists diagnosed the subtypes of the primary tumors
according to IASLC/American Thoracic Society/European
Respiratory Society International Multidisciplinary Classi-
fication of adenocarcinoma [2]. Diagnosis of AIS or MIA
was based on the HE staining (Figure 1).
Immunohistochemistry of TGF-β1 in small lung
adenocarcinoma
After reviewing HE-stained sections of the tumor speci-
mens, we selected blocks from the central regions of the
tumors for further study. The paraffin-embedded tumor
tissues were cut into 4-μm-thick sections and depa-
raffinized. Small lung adenocarcinomas were then
assessed based on standard immunohistochemical (IHC)
staining using goat polyclonal anti-TGF-β1 (1:50 dilu-
tion; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), anti-goat horseradish peroxidase (1:100 dilution),
and diaminobenzidene stain (Figure 2). The TGF-β1
staining was scored using the Allred 8-unit system with
the combination of a proportion score from 0 to 5 and
an intensity score from 0 to 3. The proportion score
included the fraction of positively stained tumor cells
and was as follows: 0 = none, 1 ≤1/100; 2 = 1/100 to 1/
10; 3 = 1/10 to 1/3; 4 = 1/3 to 2/3; 5 ≥2/3. The staining
intensity score was as follows: 0 = none; 1 = weak; 2 =
intermediate; 3 = strong [13,14].
Immunohistochemical detection of micrometastasis and
isolated tumor cells in dissected lymph nodes
Isolated tumor cells and lymph node micrometastasis were
assessed in all patients based on HE staining and IHC using
AE1/AE3 antibodies. One section of the maximum cut
surface of each lymph node was immunohistochemically
Figure 1 International multidisciplinary classification of lung
adenocarcinoma. (a) Adenocarcinoma in situ. Histologic specimen
showing a tumor with atypical pneumocytes proliferating along
slightly thickened but preserved alveolar walls; (b) Minimally invasive
adenocarcinoma. Histologic specimen of a tumor exhibiting a
bronchioloalveolar growth pattern with minimal invasion. The tumor
is invading in the fibrous stroma.
Figure 2 Immunostaining adenocarcinoma in situ and
minimally invasive adenocarcinoma using an anti-TGF-β1
antibody. (a) TGF-β1-positive MIA sample. TGF-β1-positive cells are
stained brown. TGF-β1-positive cells are predominantly observed in
the tumor itself. This sample has an Allred score of 6/8; (b) TGF-β1
-negative AIS sample. This sample has an Allred score of 0/8. TGF:
Transforming growth factor; AIS: Adenocarcinoma in situ; MIA:
Minimally invasive adenocarcinoma.
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cytokeratin clones using an EnVision system (DAKO
Corporation, Carpinteria, CA, USA), which was used to
detect the presence of micrometastases and isolated
tumor cells. A result was considered positive if positive
cell clusters or individual cells with the appropriate
tumor cell morphology were recognized. As proposed
by the 7th edition of the TNM staging system [12], iso-
lated tumor cells were not considered as positive, but
were defined as pN0(i+) in this study.Statistics
Group data were expressed as means ± SD. Categorical
data were compared using the χ2 test. The significance
of individual differences was evaluated using the
Wilcoxon test. Values of P <0.05 were considered to besignificant. JMP IN 8.0.2 software (SAS Institute, Cary,
NC, USA) was used for all statistical evaluations.
Results
There were no differences between the AIS and MIA
groups with respect to age, gender, nodal involvement or
pathological stage; however, tumor size was greater in
the MIA group than the AIS group (Table 1). Table 2
shows the incidence of TGF-β1 expression detected
upon immunohistochemical examination in the AIS and
MIA groups. Figure 3 shows the differences in TGF-β1
immunostaining between AIS and MIA scored using the
Allred method. The rate of TGF-β1 positivity was signifi-
cantly (P <0.05) higher in the MIA group (65.2%; 15/23)
than the AIS group (27.3%; 6/22). Similarly, the median
Allred score for TGF-β1 expression was significantly
Table 2 Incidence of TGF-β1 expression in the AIS and
MIA groups
TGF-β1 expression positive stain (%)
AIS (n=22) 27.3
MIA (n=23) 65.2*
AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, *P <0.05.
Figure 4 Isolated tumor cells in a dissected lymph node.
Isolated tumor cells were detected by immunostaining using anti-
cytokeratin antibody in a patient diagnosed with MIA. The patient’s
pathological stage was pT1aN(i+)M0, Stage IA.
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(3.0 (range 0–6) vs. 0.5 (range 0–5)).
One instance of lymph node metastasis was detected
in the MIA group using HE and IHC staining with AE1/
AE3 antibodies. In addition, isolated tumor cells were
found in a second patient diagnosed with MIA (Figure 4).
This patient was staged as pT1aN0(i+)M0. The overall
survival rates differed somewhat between AIS and MIA
patients (100% vs. 89.5%), but that difference did not
reach statistical significance (P = 0.093).
Discussion
The results of the present study suggest that patients
with MIA show greater expression of TGF-β1 than pa-
tients with AIS, as indicated by the significantly greater
TGF-β1 positivity rate and Allred score. In addition, HE
and IHC staining revealed that lymph node metastasis
and isolated tumor cells were only present in the MIA
group. Thus, TGF-β1 expression by adenocarcinomas
appears to be an important factor associated with clini-
copathological microinvasion in patients with small lung
adenocarcinoma.
TGF-β increases the invasiveness of cancer cells by in-
creasing their proteolytic activity and promoting their
binding to cell-adhesion molecules [15]. In an earlier
study, we demonstrated that tumor-derived TGF-β1Figure 3 Allred score system devised to score results from
immunohistochemical tests of TGF-β1. Differences in TGF-β1
immunostaining between AIS and MIA scored using the Allred
method; *P <0.05.induces dendritic cell apoptosis within lymph nodes in
non-small cell lung cancer [9], and that overexpression
of TGF-β1 by tumor cells promotes lymph node metas-
tasis in mice [11]. Consistent with those findings, the ef-
fects of TGF-β1 on angiogenesis, stroma formation and
immune function appear to further support tumor pro-
gression and invasion [16,17]. AIS is a small localized
adenocarcinoma in which growth is restricted to neo-
plastic cells along preexisting alveolar structures without
fibrous stromal invasion. In MIA, by contrast, tumor
cells have infiltrated the myofibroblastic stroma. In many
diseases, excessive TGF-β contributes to a pathological
excess of tissue fibrosis that compromises normal organ
function, a topic that has been the subject of several re-
views [18-20]. However, we provide no direct evidence
of the mechanism by which TGF-β1 increases tissue fi-
brosis in MIAs.
The Noguchi classification [21] is predictive of out-
come in patients with small adenocarcinomas, with type
D, E, and F tumors showing a worse outcome than the
other tumor types. However, the majority of small
adenocarcinomas are classified as type C, so that sub-
classification of type C tumors does seem necessary.
Tumors that meet the criteria for AIS were formerly
classified as bronchioloalveolar carcinoma based on the
strict definition of type A and type B adenocarcinomas
from the 1995 Noguchi classification [21]. MIAs are tu-
mors showing lepidic growth and a small (≤5 mm) area
of invasion. The MIA invades areas of stromal fibrosis in
an acinar pattern. Nearly all type C adenocarcinomas
can be classified as MIAs. The outcome of patients with
adenocarcinomas with diameters of 2 cm or less can be
predicted using the following scoring system based on
three histological criteria: 1) the tumor is lymphovascular
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oma component is >10 mm in diameter; and 3) the
percentage of the solid, cribriform, and/or papillary com-
ponents is ≥30% of the entire tumor volume [22]. Patients
whose MIAs have a non-bronchioloalveolar carcinoma
component ≤5 mm show 100% survival [22,23]. Consist-
ent with that finding, no difference in survival was ob-
served between AIS and MIA in the present study.
However, nodal involvement was observed in 2 of 23 pa-
tients with MIA. We therefore suggest that it would be
problematic to conduct limited surgery for MIA patients
with micrometastasis or isolated tumor cells, though some
MIAs may be candidates for limited surgery.
Conclusions
In conclusion, our findings suggest that patients with MIAs
have both a significantly greater rate of TGF-β1 positivity
and higher TGF-β1 Allred scores than patients with AIS.
However, because we do not provide direct evidence of the
mechanism by which TGF-β1 increases tissue fibrosis in
MIAs, and we examined only a limited number of patients,
further studies will be needed to more precisely define the
role played by tumor-derived TGF-β1 in determining the
invasiveness of adenocarcinoma of the lung.
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